Risk factors that may influence the decision to pause treatment include: Being in the dose-escalation phase of GLP-1 therapy Experiencing active gastrointestinal symptoms (nausea, vomiting, bloating) Having known gastroparesis or other conditions affecting gastric emptying Taking concurrent medications that further delay gastric emptying (e.g., opioids) Undergoing procedures with higher aspiration risk (e.g., emergency surgery, airway surgery) If your anaesthetist or surgical team advises temporary cessation based on your individual risk assessment, the timing will depend on the specific medication: Daily injections (such as liraglutide): Typically paused 24 hours before surgery Weekly injections (such as semaglutide, dulaglutide): Often paused with the last dose given at least 7 days before surgery Oral semaglutide (Rybelsus): Usually paused 24 hours before surgery However, these timings may vary according to local NHS Trust protocols and individual clinical assessment

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A (2014) Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Firstly, increase your water intake
Early and robust liver fat loss suggests that initiating treatment soon after diagnosis may yield optimal results
The subcutaneous tissue in the abdominal area provides reliable absorption of these medications
The KwikPens have a dose knob, but Lilly labels them as delivering four fixed doses and does not provide a validated click-to-milligram conversion for fractional dosing